[Tricuspid regurgitation in 2023 : Where are we with the treatment of the forgotten valve?].

Meier, David; Akodad, Mariama; Tzimas, Georgios; Doguet, Fabien; Jelisejevas, Julius; Boone, Robert H; Sathananthan, Janarthanan; Blanke, Philipp; Leipsic, Jonathon A; Muller, Olivier; Webb, John G; Praz, Fabien (2023). [Tricuspid regurgitation in 2023 : Where are we with the treatment of the forgotten valve?]. Revue médicale suisse, 19(817), pp. 477-485. Médecine & Hygiène 10.53738/REVMED.2023.19.817.477

Full text not available from this repository.

The negative impact of tricuspid regurgitation on prognosis in now well established. It also appears clear that surgical and possibly percutaneous treatment should be performed before reaching a point of no return with advanced heart failure and deterioration of right ventricle function. Percutaneous treatment has been divided into coaptation restoration devices, annuloplasty devices, and ortho- or heterotopic valve replacement. The present article offers a brief review of diagnostic modalities beyond echocardiography, surgical treatment as well as of the multiple recent development in the percutaneous treatment of this frequent condition.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

UniBE Contributor:

Praz, Fabien Daniel

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0025-6749

Publisher:

Médecine & Hygiène

Language:

French

Submitter:

Pubmed Import

Date Deposited:

09 Mar 2023 09:14

Last Modified:

09 Mar 2023 23:27

Publisher DOI:

10.53738/REVMED.2023.19.817.477

PubMed ID:

36883709

URI:

https://boris.unibe.ch/id/eprint/179748

Actions (login required)

Edit item Edit item
Provide Feedback